Floatz logo

Hydroxyurea

Metabolic Disorders

Washington University School of MedicineSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Metabolic Disorders cohort.

Asset / SponsorPhaseRating
Monomethyl Fumarate
Washington University School of Medicine
Phase 1/2CCC
METHOTREXATE
Washington University School of Medicine
Phase 1/2CCC
CYCLOSPORIN A
Washington University School of Medicine
Phase 1/2CCC
azd2693
AstraZeneca
Phase 1CC

Same molecule, other indications

Hydroxyurea is also rated in:

beta-thalassemia majorDormant
BBB
Indicative ·
77 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
71 / 100
View asset →
thalassemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →